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“Science, my lad, is made up of mistakes but they are mistakes which it is useful to make, 
because they lead little by little to the truth.” 
Jules Verne 
  
  
  
ABSTRACT 
FOXP3+ regulatory T (Treg) cells are powerful regulators of the immune system, as shown by 
the development of multi-organ autoimmunity in mice and men upon loss or dysfunction of 
these cells. Whilst Treg cells are vital to control normal immune responses, they are also 
involved in the development of autoimmunity and the failure to combat cancer. Cytotoxic T 
lymphocyte antigen-4 (CTLA-4) is an important regulator of adaptive immune responses and 
vital for the function of Treg cells, as demonstrated by loss of function studies that result in 
similar autoimmunity as that caused by loss of Treg cells. 
The broad aim of this thesis was to gain a deeper understanding of how CTLA-4 mediated 
tolerance operates both in health and in autoimmune disease, as its role in the adult immune 
system remains ill-defined. Therefore, in study I, we developed a novel system that allows for 
the inducible depletion of CTLA-4. Loss of CTLA-4 in adulthood unleashed T cell, but 
especially Treg cell homeostasis, resulting in multi-organ lymphocytic infiltrations that 
however did not progress to fatal autoimmunity and affected different organs than congenic 
CTLA-4 deficiency did, which implies a role for CTLA-4 in thymic T cell selection. 
Furthermore, we could show that loss of CTLA-4 can have both disease promoting as well as 
protective effects, depending on the type of autoimmunity as well as the inducing agent, 
depicting the need for context specific studies. Thus, in study II, we focused on collagen-
induced arthritis (CIA) and found that CTLA-4 regulated all stages of disease as well as disease 
spreading, albeit without affecting heterogeneous T or B cell responses. Autologous responses 
were however controlled by CTLA-4 and loss of CTLA-4 could break pre-established T cell 
tolerance to type-II collagen (CII). Furthermore, we found that CTLA-4 on conventional T cells 
limited the priming of autoreactive T cells, whereas Treg cell specific CTLA-4 was necessary 
to control the inflammatory tissue attack. In study III, we analyzed CII-specific T cells and 
found that CTLA-4 could induce tolerance in individuals with an inherent T cell predisposition 
to joint reactivity. These tolerized, CII-reactive T cells were found in high frequencies in the 
liver and transfer of liver lymphocytes could induce tolerance in otherwise susceptible hosts. 
Further studies are needed to elucidate if tolerance is induced in the liver or whether tolerized 
T cells accumulate in this organ, but it opens exciting possibilities for research aiming to induce 
tolerance in arthritis patients. In study IV, we used mice defective in reactive oxygen species 
that suffer from an increased susceptibility to infections, to show that increased susceptibility 
to autoimmunity is not merely a consequence of these infections but is a separate phenomenon.   
Taken together, our data reveal the complex nature of CTLA-4 mediated regulation and the 
necessity to study antigen-specific responses. They also demonstrate the immensely powerful 
tolerance inducing abilities of CTLA-4, even in the face of enhanced self-reactivity. This 
increased understanding will be of importance for finding novel treatment strategies for patients 
suffering from autoimmunity.  
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1 THE IMMUNE SYSTEM IN A NUTSHELL 
Our bodies are exposed to millions of potentially infective agents every day but we seldom get 
sick thanks to our powerful immune system that is well equipped for fighting off bacteria, 
fungi, viruses and parasites. However not all microorganisms are harmful, like the commensal 
bacteria of the gut and our immune system has learned to tolerate these beneficial 
microorganisms instead of fighting against them. 
The immune system is a complex network of highly specialized cells, organs, tissues and 
molecules that all work together in protecting the human body against pathogens by 
discriminating self from non-self (1, 2) and dangerous from innocuous antigens (3). Herein, 
every immune response must fulfill four tasks: (I) invading harmful pathogens must be 
recognized, (II) the infection has to be cleared or at least limited to prevent spreading, (III) the 
established immune response has to be tightly regulated and shut down once the infection is 
cleared to avoid harm to the body by excessive inflammation and (IV) an immunological 
memory has to be generated, enabling the immune system to react faster to a subsequent 
infection caused by the same pathogen.  
Our immune system consists of an innate and an adaptive arm. These two are inadvertently 
linked and a successful immune response usually requires both the speed of the innate as well 
as the specificity of the adaptive system, which is amongst others, controlled by cytotoxic            
T lymphocyte antigen-4 (CTLA-4), a powerful regulator of the adaptive immune response.    
1.1 THE INNATE IMMUNE SYSTEM 
The innate immune system is considered as the fast first line of defense after pathogens have 
crossed the body’s tissue barriers consisting of skin and mucosal epithelia. Cells of the innate 
immune system, such as macrophages, dendritic cells (DCs), neutrophils and mast cells cannot 
distinguish between different antigens but they can distinguish self from non-self with the help 
of pathogen recognition receptors (PRRs) that recognize pathogen-associated molecular 
patterns (PAMPS), found on pathogens but not on own cells. Innate cells fulfill three important 
functions: (I) pathogens are phagocytosed and destroyed, (II) cytokines and chemokines are 
produced that increase vascular permeability and attract other immune cells, amongst them 
adaptive cells, to the site of infection and (III) antigens of engulfed pathogens are presented via 
major histocompatibility complex (MHC) molecules to adaptive cells that lack PRRs to alert 
them to the presence of pathogens.  
Molecular components of the innate immune system are, amongst others, antimicrobial 
peptides and the complement proteins. Antimicrobial peptides are small molecules that damage 
and kill microbes either by attaching themselves to and creating pores in bacterial membranes 
or by binding to molecules inside of bacteria and interfering with bacterial replication. The 
complement system consists of a number of small proteins that attach themselves to cell 
membranes, starting a cascade of cleavages that finally results in the creation of a pore in the 
cell membrane. Apart from lysing cells, the complement cascade releases powerful 
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chemotactic molecules that alert and recruit other immune cells to the site of infection. The 
complement system can either be activated spontaneously or by cross-linking of antibodies. 
Spontaneous activation can in principle occur on any membrane but is usually prevented on 
the body’s own cells by inhibitory molecules. 
Often, the innate immune system is sufficient to combat an infection but since it does not 
possess a memory function it cannot prevent an infection from reoccurring and sometimes all 
the innate system can do is to hold an overwhelming infection at bay until the more specific 
and potent yet slow to start adaptive immune system has gotten in gear.  
1.1.1 Reactive oxygen species 
Biological processes are subject to redox regulation, through a system of oxidases and 
reductases. For example, cysteines in thiol-containing proteins can be oxidized and 
subsequently form covalent disulfide bridges which render a protein’s 3D confirmation more 
rigid. Furthermore, cysteine oxidation has been shown to change antigenicity of peptides (4). 
Reactive oxygen species (ROS) are formed in mitochondria as part of the cellular metabolism 
of oxygen or in phagocytes upon stimulation of the NADPH oxidase 2 (NOX2) complex, a 
process called phagocytic burst that is crucial for host defense against bacteria. The NOX2 
complex can be found both at the plasma membrane as well as at phagosomal membranes, 
releasing ROS both intra- and extracellular. Compared to other ROS species, H2O2 has a long 
half-life and can freely diffuse through lipid membranes, opening the possibility to affect cells 
other than the ROS producing one. A naturally occurring polymorphism in the neutrophil 
cytosolic factor 1 (Ncf1) subunit of the NOX2 complex, which results in a truncated Ncf1 
protein and absence of NOX2 derived ROS, renders rats and mice more susceptible to 
experimental arthritis, rebutting the dogma that ROS is always pro-inflammatory and 
pathogenic (5, 6). Instead, it has been shown that ROS mediated oxidation of the surface of 
T cells renders them less arthritogenic (7) and that absence of ROS can break both pre-
established T- and B cell tolerance to type-II collagen in mice (8, 9).           
1.2 THE ADAPTIVE IMMUNE SYSTEM 
Cells of the adaptive immune system have specialized cell surface receptors enabling them to 
distinguish between pathogen types and strains. Their effector functions are therefore much 
more targeted and thus can be more powerful without causing tissue damage. The adaptive 
immune system consists of T- and B cells that are derived from the same multipotent 
hematopoietic stem cell in the bone marrow. T cell progenitors travel from the bone marrow to 
the thymus where they develop into T cells, which undergo an intricate selection process that 
leaves only very few T cells to exit into the periphery. The main function of T cells involves 
cell-mediated immune responses and will be explained in more detail in section 1.4. B cell 
progenitors also undergo a differentiation and selection process, but unlike T cells, this happens 
in the bone marrow. The main function of B cells involves humoral responses, i.e. the 
production of antibodies. Both T and B cells can develop a memory, a quality that is utilized 
in the vaccination of healthy people against common pathogens. 
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1.3 ANTIGEN PRESENTATION 
T- and B cells cannot be activated by the pathogen itself but require presentation of pathogen 
associated antigens on MHC molecules of innate cells. Every nucleated body cell is capable of 
presenting endogenous antigens on MHC class-I molecules to cytotoxic CD8+ T cells. The 
majority of endogenous antigens are self-antigens but can also stem from bacteria and viruses 
that hide inside host cells. On the contrary, only so-called professional antigen-presenting cells 
(APCs), such as dendritic cells, macrophages and B cells, are capable of taking up and 
presenting exogenous antigen on MHC class-II (MHC-II) molecules to CD4+ T cells.  
As already mentioned, the function of MHC molecules is to bind and present peptides to T cells. 
The MHC is polygenic, consisting of more than 200 genes in humans. Every MHC molecule 
has a unique peptide-binding groove that is capable of binding different peptides with various 
affinities, creating a tremendous number of peptides that can be recognized by any individual. 
Furthermore, the MHC is also polymorphic, which means that there are many variants of the 
same gene found amongst a population. This ensures that there will always be some individuals 
who have the right MHC variant to recognize any given pathogen and this ensures the survival 
of the population as a whole.  
APCs that have taken up pathogens upregulate MHC-II and costimulatory molecules, enabling 
them to activate and prime naïve T cells in secondary lymphoid organs such as spleen and 
lymph nodes.  
1.4 T CELLS 
T cells recognize peptides presented on MHC by their highly specific T cell receptor (TCR). 
Similar to MHC molecules being able to bind a huge variety of different peptides, TCRs are 
able to recognize huge varieties of presented peptides. A TCR is a heterodimer consisting of 
an α- and a β-chain that are generated through random somatic combination of three gene 
segments that each exist in multiple copies. This combinatorial diversity is even further 
increased by the many possible different combinations of α- and β-chains resulting in a unique 
TCR repertoire of approximately 25 million specificities in any individual (10).  
T cells can be divided into CD8+ and CD4+ subtypes. CD8+ cytotoxic T-lymphocytes (CTL) 
recognize peptides presented on MHC class I that are mostly derived from endogenous 
pathogens that infect cells. CTLs have the ability to kill these infected cells with preformed 
granules containing cytotoxic molecules, such as granzymes, to prevent systemic propagation 
of the pathogen. 
CD4+ T cells recognize peptides from endogenous pathogens that were phagocytosed and are 
then presented on MHC-II. They are also called T helper cells since they help infected 
macrophages to increase their phagocytic activity and B cells to produce antibodies. T helper 
cells can be further divided into various subtypes such as Th1, Th2 and Th17 that differ in their 
effector functions and cytokine production. A subtype of CD4+ T cells, forkhead box P3+ 
(FOXP3) regulatory T cells, will be described in detail in section 3. 
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1.4.1 T cell activation 
Naïve T cells circulate through secondary lymphoid organs until they meet an APC that 
presents their specific antigen upon which they undergo clonal expansion. To fully activate and 
prime a naïve T cell three signals are required:  
I. Recognition of the MHC : peptide complex 
via the TCR 
II. Interactions between costimulatory 
molecules expressed on activated APCs 
such as CD80/86 and CD28 on T cells 
III. Cytokines expressed by activated APCs, 
such as IL-12 and type I interferons for 
differentiation into T cell subtypes 
If one or more of the three signals is missing, T cells do not become primed but are instead 
rendered tolerant or anergic, a phenomenon important in upholding tolerance to self-peptides 
in the absence of inflammation.  
Equally important as the activation is the termination of T cell responses once the pathogen has 
been cleared, to avoid tissue damage by excessive inflammatory responses. To a certain degree, 
immune responses are self-limiting as antigen specific lymphocytes no longer encounter their 
antigen once the infection is cleared and therefore receive no further stimulation, resulting in 
the death of the majority of these cells. A few however survive and turn into memory cells – 
long lived resting cells residing in the bone marrow that can very quickly fight off reoccurring 
infections with the same pathogen. Another way of terminating T cell responses is through 
engagement of co-inhibitory receptors such as CTLA-4. Naïve T cells express very low levels 
of CTLA-4 but this expression is upregulated in response to TCR ligation and reaches 
maximum levels after 24-48 hours (11). CTLA-4 outcompetes CD28 for binding to 
costimulatory CD80/86 molecules on APCs and induces cell cycle arrest and will be discussed 
in more detail in section 4. 
1.5 B CELLS 
B cells have very diverse, specialized receptors on their surfaces that are similar to TCRs with 
the difference that B cell receptors (BCR) can directly recognize antigens without the help of 
MHC molecules. In order for naïve B cells to turn into antibody producing plasma cells, 
additional help/stimulation by CD4+ helper T cells is needed. Antibodies will initially have the 
same specificity as the corresponding BCR that activated them, but plasma cells additionally 
undergo a process called affinity maturation, meant to increase antibody affinity. Antibodies 
bind to their specific target antigen and thereby either neutralize for example a toxin or mark a 
pathogen for destruction, called opsonization. Opsonized targets are eliminated either by 
phagocytic cells or by activation of the complement system, both of which have receptors that 
recognize conserved structures present on every antibody.  
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2 IMMUNOLOGIC TOLERANCE 
Every immune response comprises the release of tissue damaging factors and death of cells, 
resulting in cell debris and inflammation. Therefore, it is important to locally contain the 
immune response, to terminate it once the pathogen has been eradicated and to ensure that the 
response is limited to harmful microorganisms. Intricate control mechanisms have evolved 
both during lymphocyte development and also in the periphery to tailor the immune system to 
only respond to pathogens. Yet sometimes these control mechanisms fail and the body’s own 
structures are attacked, resulting in loss of tolerance to self and the development of autoimmune 
diseases such as rheumatoid arthritis, multiple sclerosis or type I diabetes.  
2.1 CENTRAL TOLERANCE 
T cell precursors travel from the bone marrow to the thymus where they undergo a process of 
positive and negative selection with the aim to select only those T cells that recognize              
self-MHC:non-self peptide complexes.  
Positive selection of CD4CD8 double positive T cells occurs in the thymic cortex and is 
mediated by MHC expressing thymic cortical epithelial cells with the goal to select only those 
T cells that have rearranged their TCR chains in a fashion that allows recognition of self-MHC. 
Depending on whether MHC-I or -II is recognized, T cells will continue to express only CD8 
or CD4 respectively. T cells that recognize neither class of MHC undergo apoptosis due to the 
lack of survival signals (12).  
Negative selection of CD4 and CD8 single positive T cells occurs in the thymic medulla and is 
mediated by medullary thymic epithelial cells and DCs with the goal to eliminate those T cells 
that recognize self-peptides with high affinity. Medullary thymic epithelial cells express the 
autoimmune regulator (AIRE) gene, which enables them to express most peripheral tissue-
restricted self-antigens. Only those T cells that have intermediate TCR affinities for self-
peptides are allowed to leave the thymus and form the peripheral TCR repertoire, whereas those 
with absent or too high affinities undergo apoptosis (12). However, not all T cells with a high 
affinity for self-peptides are negatively selected but some turn into FOXP3+ regulatory T cells 
that will be discussed in more detail in section 3.  
2.2 PERIPHERAL TOLERANCE 
Thymic negative selection should in principle get rid of all high affinity self-reactive T cells. 
However, since every TCR harbors a certain degree of cross-reactivity to other antigens, a too 
stringent negative selection would dangerously limit the TCR repertoire that is able to respond 
to pathogens. Therefore, negative selection is not complete and low-affinity auto-reactive 
T cells can be found in healthy individuals (13). It is thus necessary to implement a second 
layer of tolerance to control these auto-reactive T cells in the periphery. Several different 
pathways of peripheral tolerance exist that are not mutually exclusive, as several tolerant states 
can exist in parallel in vivo depending on the dose (14) and location (15) of antigen.  
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2.2.1 Ignorance 
Ignorance entails that self-antigens are either expressed in such small amounts that they are 
below the threshold for T cell activation, are expressed in immunoprivileged organs that are 
not surveyed by the immune system, such as the testes and anterior chamber of the eye, or are 
separated from T cells through physical barriers such as the blood-brain-barrier around the 
central nervous system (CNS). This entails however that these self-reactive cells are not 
centrally deleted and that they can cause autoimmunity if activated elsewhere, as is the case in 
multiple sclerosis (16). 
2.2.2 Anergy and Exhaustion  
Anergy, or non-responsiveness, implies the functional inactivation of T cells after encounter 
with antigen. Anergic T cells are refractory to subsequent stimulation with antigen but survive 
for extended periods of time (17). Anergy can be divided into two classes. (I) Clonal anergy 
that is induced in naïve T cells that meet their cognate antigen in the absence of CD28 
costimulatory signals (18) and (II) division arrest anergy (also called adaptive tolerance or in 
vivo anergy) that is induced in activated T cells by stimulation through co-inhibitory CTLA-4, 
resulting in a failure of cell cycle progression (19, 20). Clonal but not division arrest anergy 
can be reversed by addition of IL-2 (21). Anergic T cells can be identified by increased surface 
expression of CD73 and folate receptor 4 (FR4) (22) but should not be confused with regulatory 
T cells, that constitutively express high levels of both CD73 (23) and FR4 (24). Of special 
interest in this context is that anergic T cells have been shown to generate precursors for 
peripheral regulatory T cells (25), further reinforcing the tolerogenic concept of anergy.   
Another form of T cell non-responsiveness, called exhaustion, occurs in chronic infections with 
persistent antigen. At first sight, T cell exhaustion might not appear to be a tolerance 
mechanism but rather a sign of defeat. However, persistent immune responses in chronic 
infections that have no prospect of eradicating the pathogen cause extensive tissue damage and 
thus reaching a balanced state of co-existence might be the better option (26). High expression 
of programmed cell death protein 1 (PD-1) in combination with reduced proliferation is 
commonly used to identify exhausted T cells (27). PD-1 is a co-inhibitory receptor that, 
similarly to CTLA-4, is rapidly upregulated on activated T cells and targets TCR proximal Akt 
signaling, however by a different mechanism (28), leading to inhibition of T cell proliferation 
and cytokine production (29). Contrary to CTLA-4 ligands that are exclusively expressed on 
APCs, ligands for PD-1 have a much broader expression and can also be inducibly expressed 
in non-lymphoid tissues. Therefore it has been suggested that CTLA-4 might be more 
important for tolerance induction whereas PD-1 might be more important for the long-term 
maintenance of tolerance at the local tissue site (30). Of note, exhausted T cells are not inert 
but have residual function that can often be restored upon blockade of PD-1, especially in 
combination with other co-inhibitory blocking agents (31-33).  
Even though anergy and exhaustion have different molecular signatures (34), the resulting         
T cell phenotypes are quite similar and can therefore be difficult to distinguish. Since most of 
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the knowledge about anergy stems from CD4+ T cells whereas exhaustion has been extensively 
studied in CD8+ T cells during viral infections, one tends to simply call T cell unresponsiveness 
anergy in CD4+ T cells and exhaustion in CD8+ T cells, without carefully distinguishing 
between the two.  
2.2.3 Apoptosis 
Unarguably, the safest way of controlling autoreactive T cells in the periphery is to simply 
delete them by inducing apoptosis. However, if all weakly self-reactive T cells were deleted, 
this would dangerously limit the TCR repertoire and therefore the ability to adequately respond 
to invading pathogens. Hence this mechanism needs to be tightly controlled. Peripheral 
deletion is most commonly seen in the retraction of antigen-specific T cell clones after an 
infection has been cleared and can be mimicked in vitro by TCR stimulation plus IL-2 followed 
by T cell reactivation several days later (35). This process is also called activation induced cell 
death (AICD), as it is the TCR mediated activation that sensitizes T cells for apoptosis, whereas 
naïve T cells are highly resistant (36). One pathway of apoptosis induction involves Fas:Fas 
ligand mediated activation of caspases. Activated lymphocytes express both Fas and Fas ligand 
and can thus kill each other or be killed in Fas ligand expressing tissues (37). The latter has 
been shown to be an important mechanism of tolerance in immunoprivileged organs, especially 
the eye (38). 
2.2.4 Dominant suppression 
Another powerful way of harnessing immune responses is dominant suppression, which entails 
active suppression by peripheral regulatory cells. Dominant suppression can involve the 
production of anti-inflammatory cytokines, expression of regulatory molecules, cytokine 
deprivation or reduced APC costimulatory function. In principle can any lymphocyte have 
regulatory functions in certain circumstances and this has been described for CD8+ T cells, B 
cells, DCs and macrophages but most often dominant suppression is associated with FOXP3+ 
Treg cells. However, at least two more peripherally induced CD4+ regulatory T cells have been 
described: IL-10 secreting Tr1 cells and TGF-β secreting Th3 cells that play important roles in 
mucosal and oral tolerance (39, 40).  
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3 FOXP3+ REGULATORY T CELLS 
The idea of regulatory T cells goes back to 1969 and the classical day 3 thymectomy 
experiments by Nishizuka and colleagues that resulted in autoimmunity (41). A year later, 
Gershon et al. showed that these suppressor cells originated from the thymus (42). In the 
following years however, the field crashed as the putative suppressive molecule I-J was shown 
to be non-existent (43) and hence for the next decades the field was discredited as “no realm 
of immunology has less credibility than that of suppressor T cells” (44). Only 25 years later, in 
1995, were suppressor cells rediscovered by Sakaguchi who identified them as being 
CD4+CD25+ and renamed them regulatory T cells (45). In 2001, mutations in the X-linked 
Foxp3 gene were shown to be the underlying cause for autoimmunity in scurfy mice (46) and 
in immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) patients 
(47) and in 2003 FOXP3 was identified as the transcriptional master regulator of regulatory         
T cell (Treg) development in mice, overexpression of which could render naïve CD4+ T cells 
suppressive (48, 49).       
3.1 DEVELOPMENT  
FOXP3+ Treg cells can be selected in the thymus (tTreg; often also referred to as natural nTreg) 
or be peripherally induced from naïve CD4+ T cells in vivo (pTreg) or in vitro (iTreg).  
tTreg cells are selected in the thymus starting from the CD4CD8 double positive but mostly in 
the CD4 single positive T cell stage. Unlike conventional T cells, tTreg cells are selected based 
on high affinity to self-peptides and the strength of the TCR signal has been shown to correlate 
with the degree of FOXP3 induction with the exception for the very highest affinities that result 
in negative selection (50-52). Thus, Treg cells express TCRs with affinities that fall between 
those of positive and negative selection (53). Despite the view of FOXP3 being the master 
regulator of Treg lineage specification, FOXP3 expression alone is in fact not sufficient to 
confer a full Treg phenotype as illustrated by the fact that activated human conventional T cells 
(Tconv) transiently express FOXP3 without adopting a suppressive phenotype and that 
retroviral overexpression of FOXP3 in Tconv cells only reproduced one third of the Treg cell 
signature genes (54). Indeed, it has been shown very recently, that FOXP3 is in fact not required 
for the induction of most Treg cell signature genes, but that it augments a pre-established 
pattern of gene expression and repression. Instead, patterns of Treg cell specific super-
enhancers that are established by the genome organizer Satb1 and potentially others, are active 
before the expression of FOXP3 and might be a key-determinant in Treg cell lineage 
specification (55). Induction of a full Treg phenotype additionally requires the establishment 
of a Treg specific demethylated region (TSDR). The TSDR is an evolutionary conserved CpG 
rich element within the Foxp3 locus (56), whereas the nTreg-Me additionally includes Treg 
signature genes such as CTLA-4 (57). tTreg cell-type CpG hypomethylation occurs gradually, 
starting in the thymus and being finished in the periphery. It requires TCR ligation with self-
ligands but is established independently of FOXP3 expression as illustrated by retroviral 
overexpression of FOXP3 in Tconv cells as well as FOXP3 expressing iTreg cells that both 
lack a fully demethylated TSDR (54, 57). A demethylated TSDR is crucial for stable FOXP3 
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expression (58) and it has been shown that Treg cells that express FOXP3 but lack a 
demethylated TSDR are unstable and can lose their suppressive function (59).  
Thymic induction of Treg cells further 
depends on the availability of IL-2 and 
CD28 costimulation to induce FOXP3 
expression. IL-2, a T cell survival cytokine, 
can be produced by every T cell with the 
exception of Treg cells. In the thymus, IL-2 
is produced locally by antigen-bearing DCs 
and developing Treg cells compete for it, 
limiting the size of the Treg cell niche (60). 
The requirement for CD28 costimulation is 
independent of CD28 induced IL-2 
production and rather paradoxical since 
CD28 costimulation in developing 
conventional thymocytes induces negative 
selection through apoptosis (61). Treg cells 
continue to depend on IL-2, TCR and CD28 
signaling throughout their entire life (62-64). The size of the Treg cell niche is further 
controlled by intraclonal competition as Treg cells develop most efficiently if only a minor 
fraction of thymocytes expresses any given TCR and will fail to develop in full TCR transgenic 
mice on the RAG background unless their cognate antigen is expressed simultaneously (65).  
Treg cells can also be induced in the periphery from naïve CD4+ T cells. Contrary to tTreg 
induction that requires high affinity TCR signaling, induction of FOXP3 in the periphery 
requires suboptimal TCR stimulation with low doses of a high affinity agonist (66). Since it is 
the cumulative TCR stimulation that rules over FOXP3 induction, increasing the TCR 
stimulation through time or peptide density can enhance FOXP3 induction efficiency. 
However, those “forced” FOXP3+ cells are unstable compared to the “unforced” ones and 
hence ligand potency and density are non-interchangeable factors (67). Interestingly, it has 
been shown that the specificity of tTreg and pTreg cells also differs. Whilst tTreg cells are 
specific for high affinity self-antigens, pTreg cells have been shown to be either specific for 
low affinity self-antigens or for antigens from colonic commensal microbiota (68, 69). Indeed, 
the gut appears to be a microenvironment very favorable for pTreg cell induction (70) and 
specific ablation of pTreg cells by knocking out CNS1, an intronic Foxp3 enhancer, does not 
result in systemic autoimmunity but in local autoimmunity at mucosal interfaces along with 
changes in the composition of gut microbiota (71). However, studies in germ-free mice have 
yielded opposing results on whether or not pTreg cells are affected by loss of the microbiota 
(72, 73), which could be due to the inability to selectively study pTreg cells or due to microbial 
differences in germ-free and SPF colonies. Cytokines and especially TGF-b have an important 
role in the induction of pTreg cells, whereas cytokines that induce the differentiation of other 
T helper cell types inhibit pTreg cell differentiation (74). 
Figure 1Development of Treg cells in the thymus. Ohkura et al. 
Immunity Review 2013 
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In vitro, naïve CD4+ T cells can be induced to become FOXP3 expressing iTreg cells by 
stimulation through the TCR in the presence of TGF-b (75) and IL-2 (76). Addition of retinoic 
acid can further increase the efficiency of iTreg cell generation (77, 78). Furthermore, 
expression of high amounts of FOXP3 in iTreg cells requires upregulation of CTLA-4 (79). 
There is significant debate on whether iTreg cells suppress equally well as nTreg and pTreg 
cells and their therapeutic use is further hindered by their demonstrated instability caused by 
only partial demethylation of the TSDR (56, 59). 
3.2 PHENOTYPE 
Whilst there are many cells that can acquire suppressive abilities in the immune system, 
FOXP3+ tTreg cells are unique because they are developmentally specialized for just this 
purpose. FOXP3+ T cells commonly express molecules that are associated with anergy in 
Tconv cells, like CTLA-4, PD-1, FR4 and CD73 and do not proliferate upon stimulation via 
the TCR in vitro in the absence of other cells.  
Mouse Treg cells can be specifically identified by their expression of FOXP3 or if viable cells 
are needed based on CD4+CD25hi expression. Attempts to distinguish between tTreg and pTreg 
cells based on higher expression of Helios and Neuropilin-1 (Nrp-1) on tTreg cells (80-82) 
were soon questioned, as both Helios and Nrp-1 can be induced in peripheral Treg cells (83, 
84) and both Helios+ and Helios- tTreg cells coexist in humans (85). Despite studies showing 
that neither Helios nor Nrp-1 can distinguish between tTreg and pTreg cells (86), no consensus 
has been reached and due to the lack of better alternatives, many studies continue to use these 
markers. LAP, a component of latent TGF-b, is bound to tTreg cell membranes through the 
anchoring protein GARP and has also been discussed as a tTreg marker but at least in mice, 
GARP can also be expressed by pTreg and iTreg cells (87, 88). 
In humans, Treg cells cannot be identified solely by the expression of FOXP3 or CD25, since 
activated human Tconv cells can transiently express FOXP3 and a large percentage expresses 
high levels of CD25, whereas naïve Treg cells can have lower CD25 expression. Instead, a 
combination of various cell surface markers, such as CD62L, CD127, GITR, CD73, CD39 
CD45RA, CD45RO, ICOS and HLA-DR is used to identify different subpopulations of human 
Treg cells (89). 
3.3 FUNCTIONS 
Treg cells are a double-edged sword. They are of major importance to control normal immune 
responses and to uphold tolerance to self but are also involved in autoimmunity and failure to 
combat cancer. For example, Treg cells have been shown to accumulate or be induced at tumor 
sites and depletion of Treg cells rescues mice from succumbing to cancer (90).  
Just like any other T cell, Treg cells need to be activated through their TCR. However, once 
activated, they can suppress in an antigen non-specific manner. Treg cells have numerous ways 
of suppressing target cells, as elaborated below and the exact impact of each pathway remains 
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to be elucidated. However, it appears that the location, the state of the immune system and the 
subtype of Treg cell all influence which pathway predominates in a given situation (91).  
3.3.1 Regulation of T cell function 
Treg cells can directly inhibit other T cells through various mechanisms, some of which are 
listed below. 
3.3.1.1 IL-2 Inhibition/Deprivation 
Treg cells do not produce the T cell survival factor IL-2 themselves due to FOXP3 mediated 
gene repression and are thus dependent on IL-2 produced by other T cells for their survival 
(92). Since Treg cells constitutively express high levels of the high-affinity IL-2 receptor          
a-chain CD25, they can effectively take up IL-2 from the periphery and this IL-2 consumption 
has been suggested as a suppressive mechanism of Treg cells (93). Furthermore, Treg cells 
have been shown to inhibit production of IL-2 mRNA in responder Tconv cells (94).  
3.3.1.2 ATP degradation 
Treg cells co-express high surface levels of the ectonucleotidases CD73 and CD39 that are 
involved in the catabolism of extracellular nucleotides such as ATP to immunosuppressive 
adenosine. Treg cells can thus increase the amount of pericellular adenosine which suppresses 
effector functions of activated Tconv cells that express the high affinity adenosine receptor 
A2A (23, 95).  
3.3.1.3 Production of anti-inflammatory cytokines 
A number of studies have implicated an important contribution of anti-inflammatory cytokines 
such as IL-10 and TGF-b to Treg cell mediated suppression in vivo (96). However, since 
physical separation of Treg cells from responder T cells abrogates suppression in vitro, the 
magnitude of influence of anti-inflammatory cytokines to Treg cell function remains debated 
(94). This is further illustrated by the lack of spontaneous autoimmunity in mice deficient for 
Treg cell specific TGF-b (97), whereas mice deficient for Treg cell specific IL-10 suffer from 
inflammation that is restricted to environmental surfaces such as the skin, lung and colon (98).  
IL-35, a relatively new inhibitory cytokine of the IL-12 heterodimeric cytokine family, 
consisting of the Ebi3 and Il12a chains, is constitutively secreted by Treg cells and secretion 
is further potentiated during active suppression of Tconv cells. Treg cells from either Ebi3 
knock-out (KO) or Il12a KO mice are less suppressive in vitro and fail to control homeostatic 
expansion or cure inflammatory bowel disease in vivo. Ectopic expression of IL-35 confers 
suppressive capacity on Tconv cells and recombinant IL-35 can suppress T cell proliferation 
(99).  
3.3.1.4 Cell cytotoxicity 
Besides suppressing the activation of other immune cells, Treg cells can also directly kill 
target cells. Human Treg cells have been shown to express granzyme A and to kill target cells 
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in a perforin dependent fashion (100). Similarly, mouse Treg cells have been shown to express 
granzyme B and to kill target cells in a manner that can be either perforin dependent or 
independent (101, 102). 
3.3.2 Regulation of APC function 
Instead of directly suppressing T cells, Treg cells can suppress the costimulatory capacity of 
APCs and thereby indirectly inhibit the activation of Tconv cells. 
3.3.2.1 CTLA-4 
Treg cells can reduce the costimulatory capacity of APCs by reducing their expression of 
CD80/86 and can thus inhibit the activation of T cells. This two-step process requires an initial 
lymphocyte function-associated antigen 1 (LFA-1) dependent clustering of Treg cells around 
APCs, outcompeting access of Tconv cells to APCs, and a second LFA-1 and CTLA-4 
dependent active down-regulation of CD80/86 (103). This CD80/86 downregulation is even 
seen in the presence of strong APC maturation stimuli (103, 104). In the case of CD80 but not 
CD86, reduced surface expression has been shown to be paralleled by reduced CD80 mRNA 
expression (104). An alternative mechanism for reduced expression of CD80/86 has been 
shown to involve trans-endocytosis. This process involves CTLA-4 mediated uptake of 
CD80/86 from the surface of APCs into CTLA-4+ cells, where they are degraded in lysosomes. 
This trans-endocytosis occurs within minutes after cell contact and is highly efficient as a ratio 
of 1:8 (CTLA-4:CD86) is sufficient to achieve functionally relevant depletion as seen in 
reduced APC costimulatory capacity (105).  
3.3.2.2 IDO 
Indoleamine 2,3-dioxygenase (IDO) catalyzes the first step in the catabolism of the essential 
amino acid tryptophan to kynurenine. Treg cells can induce production of IDO in DCs via 
interactions between CTLA-4 and CD80/86 (106). Induction of IDO depletes tryptophan from 
the microenvironment, thereby resulting in inhibition of T cell activation and proliferation 
(107). Furthermore, tryptophan metabolites have been shown to induce apoptosis in T cells 
(108). 
3.3.2.3 Lag-3 
Lymphocyte-activation gene 3 (Lag-3) is a CD4 homologue that can bind to MHC-II and 
induce an inhibitory signal that suppresses DC maturation and costimulatory capacity (109). 
Antibodies against Lag-3 can partially block Treg cell mediated suppression and Lag-3 
deficient Treg cells are less efficient suppressors than their wild type (WT) counterparts. The 
degree of Lag-3 mediated suppression appears to depend on both the strength of T cell 
stimulation as well as the ratio of responder to suppressor cells (110). As activated human 
T cells can express MHC-II, a direct suppression of T cells is possible.  
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3.3.2.4 Nrp-1 
Nrp-1, a cofactor for vascular endothelial growth factor, is preferentially expressed on Treg 
cells and one of the markers used to identify human Treg cells. Nrp-1 prolongs interactions 
between DCs and Treg cells (111). It remains unclear whether Nrp-1 merely marks a pool of 
activated effector Treg cells or whether Nrp-1 itself has suppressive capacity, as studies with 
blocking antibodies have led to conflicting results (111, 112). Studies with Nrp-1 deficient 
Treg cells have shown that Nrp-1 is dispensable for regulation of immune homeostasis but 
required for suppression of anti-tumor immune responses (113, 114).  
3.4 PLASTICITY AND STABILITY 
It has been suggested in recent years that Treg cells can become unstable under certain 
pathologic conditions and turn into pro-inflammatory IFNg and IL-17 producing ex-FOXP3 
effector T cells (115, 116). However, these studies have assumed that FOXP3+ Treg cells are 
tTreg cells and not a mixture of tTreg and pTreg cells. A study by Rubtsov took this into 
account and refuted tTreg instability (117). Lack of reliable surface markers to distinguish 
tTreg from pTreg cells makes reliable studies on their differential stability difficult but as it has 
been shown that pTreg cell TSDR demethylation is incomplete compared to tTreg cells, it is 
very likely that the observed degree of plasticity stems from pTreg cells. This is especially 
likely due to the developmental relationship of Th17 and extrathymically induced Treg cells, 
at least in vitro. Induction of both cell types is dependent on TGF-b but induction of Th17 cells 
requires the additional stimulation with IL-6 in order to overcome the suppressive effect of 
FOXP3 on RORgt, the master transcription factor for Th17 cells (118). Today, the predominant 
view amongst experts is that fully committed tTreg cells indeed are a remarkably stable 
population but that Tconv cells can transiently express FOXP3 and that recently induced pTreg 
cells can lose FOXP3 expression and suppressive function under high inflammatory pressure 
(119, 120).  
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4 CTLA-4 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4), a member of the immunoglobulin superfamily, 
was first discovered in 1987, as a cDNA isolated from activated CD8+ cytotoxic T cells (121). 
In 1991, CTLA-4 was shown to share close sequence homology to CD28 and to bind to the 
same CD80/86 ligands on APCs, albeit with a ~20-fold higher affinity (122, 123). At that time, 
a debate started whether engagement of CTLA-4 transmitted a positive or negative signal as 
co-cultures with T cells, APCs and soluble CTLA-4 showed decreased T cell proliferation 
(123), which could have been due to CTLA-4 on T cells being needed as a positive stimulus or 
because the CD28:CD80/86 interaction was blocked. This dispute was settled in 1995 when 
two independent groups demonstrated that loss of CTLA-4 in mice resulted in a 
lymphoproliferative disorder and early lethality, confirming a negative role beyond doubt (124, 
125).   
4.1 EXPRESSION 
CTLA-4 forms homodimers and its expression is rapidly induced on T cells in response to 
activation whereby accumulation in the immune synapse is proportional to the TCR signal 
strength (126). This rapid expression is possible due to the majority of CTLA-4 being stored 
in intracellular vesicles (127). Surface CTLA-4 is rapidly turned over through                     
clathrin-dependent endocytosis followed by either re-expression or lysosomal degradation and 
this requires the highly conserved cytoplasmic tail of CTLA-4 (128). Recently, it has been 
shown that interaction of internalized CTLA-4 with lipopolysaccharide-responsive and beige-
like anchor protein (LRBA) in recycling endosomes rescues CTLA-4 from lysosomal 
degradation and patients with homozygous loss of LRBA suffer from autoimmunity due to 
decreased surface CTLA-4 levels and thus impaired Treg cell function (129, 130). 
Contrary to the induced expression on Tconv cells, Treg cells constitutively express high levels 
of surface CTLA-4 and this is vital for their suppressive function, as loss of CTLA-4 
specifically on Treg cells results in similar, albeit delayed lethal autoimmunity as total loss of 
CTLA-4 (131). 
Apart from T cells, a few studies have reported CTLA-4 to be expressed on subsets of B cells 
(132, 133) and DCs (134), however detection of these low-levels often requires special staining 
methods and the overall expression and function of CTLA-4 on these non-T cells requires 
further clarification. 
4.2 FUNCTIONS  
CTLA-4 is an important regulator of immune homeostasis and autoimmunity. Loss of      
CTLA-4 on all T cells leads to a lymphoproliferative disorder and early lethality (124, 125). 
FOXP3+ Treg cell specific loss of CTLA-4 results in a similar phenotype, albeit a bit delayed, 
depicting a vital role of CTLA-4 for Treg cell suppressive function (131). Furthermore, resting 
human T cells can be rendered suppressive through transfection with CTLA-4 (135). Recently, 
human CTLA-4 haploinsufficiency was identified as the underlying cause for an autosomal 
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dominant immune dysregulation syndrome with autoimmune infiltration, decreased Treg cell 
CTLA-4 expression and suppressive function accompanied by a decrease in circulating B cells 
in some but not all patients (136, 137).  
CTLA-4 can function in various different ways that can be classified as either T cell 
intrinsic/autonomous or as T cell extrinisic/non-autonomous. Since CTLA-4 is expressed on 
both activated Tconv and Treg cells, both cell types can contribute to CTLA-4 mediated 
suppression, however Treg cells are more efficient/effective due to their constitutive high 
expression of CTLA-4.  
4.2.1 T cell intrinsic or autonomous functions 
T cell intrinsic functions of CTLA-4 (see figure below) include the competition with CD28 for 
access to CD80/86 ligands on the surface of APCs. Since the CTLA-4 homodimer has a        
~20-fold higher affinity to these ligands, CTLA-4 can efficiently outcompete CD28 and thus 
deprive T cells from receiving costimulatory signals through CD28. Antibody-mediated 
crosslinking of CTLA-4 leads to inhibition of T cell proliferation and overexpression of ligand-
independent CTLA-4 (see 4.3) can partially rescue the CTLA-4 KO phenotype, depicting a B7 
independent function through transmission of inhibitory signals. Indeed, CTLA-4 has been 
shown to recruit various phosphatases and to reduce phosphorylation of components of the 
TCR signaling cascade (138). However, there is no consensus between studies as to which 
molecules are affected, the cytoplasmic tail of CTLA-4 lacks an ITIM motif, gene expression 
studies failed to detect a signature of active negative regulation in CTLA-4+ cells and to this 
day no cohesive inhibitory pathway has been identified (139). A conserved motif in the 
cytoplasmic tail of CTLA-4 interacts with the protein kinase C (PKC)-h and recruits it to the 
Treg cell immune synapse, whereas in the Tconv cell immune synapse, CD28 instead recruits 
PKC-q. In the absence of CTLA-4 mediated PKC-h recruitment, due to PKC-h deficiency, 
Treg cell development is normal but their suppressive activity is markedly impaired due to the 
defective assembly of a focal adhesion disassembly complex that increases cell motility and 
serial engagement of APCs (140).  
TCR ligation reduces T cell motility which is necessary for stable T cell:APC interactions, the 
formation of the immunological synapse and the initiation of T cell priming. This process, 
called the “TCR stop signal”, can be reversed by CTLA-4 ligation, shortening the interaction 
time of T cells and APCs albeit only in Tconv but not in Treg cells (141). Additionally,    
CTLA-4 ligation induces the expression of LFA-1 on T cells, which binds to intercellular 
adhesion molecule 1 (ICAM-1) on APCs. This interaction is a prerequisite for T cell motility 
and migration through high endothelial venules and CTLA-4 thus increases T cell motility, 
further decreasing the chances of stable T cell APC interactions (138, 142).  
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Additionally, CTLA-4 has recently been shown to limit follicular helper T (Tfh) cell 
differentiation, germinal center formation, antibody production and class switching (143-146). 
Furthermore, CTLA-4 has been suggested to be involved in central tolerance through 
influencing the negative selection of T cells in the thymus, altering TCR Vα, Jα segments and 
the CDR3α composition and thus changing the peripheral TCR repertoire in TCR transgenic 
mice (147-151). Additionally, overexpression of CTLA-4 has been shown to favor                  
self-skewing of the Treg cell TCR repertoire (152). In our own study (Paper I), loss of      
CTLA-4 in adulthood resulted in multi organ autoimmunity that however did not progress to 
lethal autoimmunity and affected different organs than congenic CTLA-4 deficiency, which 
also implies a role for CTLA-4 in thymic selection (146). This is however still under debate, 
as other studies failed to see any impact on thymic T cell selection (153, 154).         
4.2.2 T cell extrinsic or non-autonomous functions 
T cell extrinsic functions of CTLA-4 (see figure below) reduce the T cell priming ability of 
APCs, thereby indirectly inhibiting T cells. CTLA-4 expressing cells can snatch CD80/86 
ligands from the surface of APCs, internalize and degrade them in lysosomes. This process 
called trogocytosis or trans-endocytosis deprives T cells from receiving CD28 costimulatory 
signals (105). The same effect is mediated by soluble CTLA-4 (see chapter 4.3) through 
blocking of access to CD80/86. Ligation of CTLA-4 with CD80/86 induces IDO in APCs, 
which is involved in the breakdown of tryptophan to immunosuppressive kynurenine and can 
render DCs prone to apoptosis or locally inhibit T cell proliferation through deprivation of 
tryptophan when IDO is secreted. Furthermore, ligation of CTLA-4 can induce the production 
of anti-inflammatory cytokines such as TGF-b and IL-10 in T cells which can inhibit T cells 
either directly or indirectly by modulating T cell stimulatory properties of APCs (138, 142).    
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4.2.3 Models of CTLA-4 function 
Combining the different mechanisms of action of CTLA-4 under steady-state or inflammatory 
conditions, two models of action become apparent that work in parallel to shape the quality and 
magnitude of the immune response.  
 
           Adapted from Egen et al. Nat. Immunol. 2002 
In situations of limited CD28 costimulation, CTLA-4 regulates the activation threshold of 
T cells, i.e. the combined strength of TCR and CD28 stimulation that is necessary to enter the 
cell cycle. In the activation threshold model, CTLA-4 will inhibit activation of autoreactive 
T cells in the absence of inflammation. Under inflammatory situations, where CD28 
costimulation is not the limiting factor, CTLA-4 becomes powerless to regulate the activation 
threshold but instead regulates the effector T cell’s capacity to divide by inhibiting several 
components of the cell cycle machinery. The degree of division regulation correlates with the 
strength of the TCR signal. This has two effects: (I) immune responses are terminated before 
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they get out of control and cause tissue damage and (II) the immune response is broadened by 
allowing more T cell clones to take part, instead of only those with the highest affinities that 
would otherwise outcompete weaker affinity clones for access to antigen bearing APCs and 
available costimulatory signals.  
4.3 CTLA-4 ISOFORMS 
The Ctla‑4 gene consists of four exons, of which exon 
1 encodes the leader peptide, exon 2 the ligand binding 
domain, exon 3 the transmembrane region and exon 4 
the short cytoplasmic tail. In addition to full length 
CTLA-4, three splice variants exist. (I) Soluble    
CTLA-4 that lacks the transmembrane domain is 
elevated in several autoimmune diseases and has been 
shown to reduce antigen-specific T cell proliferation 
and to modulate cytokine secretion (155). A SNP in the            
3’ UTR of CTLA-4 is associated with increased risk of 
developing autoimmunity and had originally been 
linked to decreased levels of soluble CTLA-4, however 
this could not be reproduced in subsequent studies (155). (II) 1/4 CTLA-4 lacks the ligand 
binding and transmembrane domain and transgenic overexpression has been shown to enhance 
disease in two models of autoimmunity and to elevate levels of auto-antibodies and 
accumulation of memory T cells in aged mice, albeit without the massive lymphoproliferation 
seen in CTLA-4 KO mice (156, 157). (III) Ligand-independent (li) CTLA-4 lacks the 
extracellular domain and thus the ability to bind to CD80/86. Overexpression of this isoform 
in CTLA-4 KO mice inhibits in vitro T cell responses, prevents tissue infiltration and 
ameliorates but does not rescue from lymphoproliferative disease (158). Treg cells from NOD 
mice that genetically lack li-CTLA-4 but were engineered to re-express physiological levels of 
the li-CTLA-4 isoform only, were shown to confer comparable disease protection as WT Treg 
cells in a type I diabetes model, whereas activated Tconv cells were significantly reduced in 
these mice. Despite reduced effector functions, Tconv cells expressing only the li-CTLA-4 
isoform, were more potent in transferring disease and protection from autoimmunity required 
the presence of full length CTLA-4. This indicates that li-CTLA-4 is important for regulating 
the tonic TCR signaling but that the ligand binding domain is required for full control of 
autoimmunity during stimulation with antigen (159). However, since ligand-independent 
CTLA-4 is only found in mice and not humans, it has not been studied extensively.  
4.4 CTLA-4 BASED THERAPY 
Antibodies that block CTLA-4 were the first successful therapeutics in the class of immune 
checkpoint therapy, which targets regulatory pathways in T cells with the aim to improve 
antitumor immune responses.  
CTLA-4 isoforms. Adapted from Valk et al. Trends in 
Immunology 2008 
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Ipilimumab is a fully human IgG1 antibody that blocks CTLA-4 and has been FDA (food and 
drug administration) approved in 2011 for the treatment of unresectable or metastatic 
melanoma as well as in adjuvant treatment of patients with cutaneous melanoma that have 
undergone tumor resection. Treatment with ipilimumab leads to an enhanced overall survival 
of patients with metastatic melanoma (160) but failed to improve overall survival of prostate 
cancer patients despite antitumor activity in a subset of patients (161). The effects of blocking 
CTLA-4 appear to be rather slow, as those melanoma patients that achieved complete remission 
required a median of 30 months to do so. However, effects were very long lasting, as the vast 
majority of patients remained remission free for extended periods, the longest lasting >99 
months (162, 163). 10-15% of metastatic melanoma patients treated with ipilimumab develop 
serious immune related adverse events that often manifest in bowel inflammation, severe skin 
problems and problems affecting the liver, nerves or endocrine system that can be                      
life-threatening and require systemic treatment with high-dose corticosteroids. Furthermore, 
many patients do not respond to treatment and to this day there are no biomarkers available to 
predict which patients might benefit from anti-CTLA-4 therapy (162). Interestingly, the anti-
cancer effects of anti-CTLA-4 therapy have been shown to be dependent on the gut microbiota, 
more specifically the outgrowth of Bacteroides fragilis upon treatment, which increased IL-12 
dependent Th1 responses and thus controlled the tumor without interrupting intestinal integrity 
(164).  
Abatacept is a fusion protein of the Fc part of human IgG1 fused to the extracellular domain of 
CTLA-4. Abatacept binds to CD80/86 molecules on APCs and thus deprives T cells from 
receiving CD28 costimulatory signals. Abatacept has been approved by the FDA for the 
treatment of rheumatoid arthritis and juvenile idiopathic arthritis in 2005. Abatacept can be 
used as a first line monotherapy but is more commonly used only in those patients that failed 
to respond to treatment with disease-modifying antirheumatic drugs (DMARDs), due to its 
high cost (165). Treatment significantly improves disease symptoms by directly or indirectly 
affecting T cells, myeloid DCs, B cells and macrophages. Furthermore, a bone protective effect 
through inhibition of osteoclast differentiation has been reported (166). Abatacept is generally 
well tolerated with the most common mild adverse events being headache, upper respiratory 
tract infections, nasopharyngitis and nausea but should not be used concomitantly with other 
biological agents as this significantly increases the incidence of serious infections and 
malignancies (167). Abatacept has undergone trials for various other indications but outcomes 
have been rather disappointing, with lack of efficacy in ulcerative colitis, multiple sclerosis, 
asthma and systemic lupus erythematosus (165).  
Belatacept is a mutated version of abatacept, differing in two amino acids, which increases its 
binding avidity to CD80 and CD86. This makes belatacept a more effective blocker of CD28 
costimulation and thus better suited to counteract transplant rejection caused by recipient 
effector T cells. In 2011 belatacept has been approved by the FDA for the treatment of kidney 
transplant recipients as treatment has been shown to significantly prolong both transplant and 
patient survival (168).   
 26 
5 AUTOIMMUNE DISEASES 
Even though most autoreactive T cells are removed during thymic selection or kept under 
control in the periphery, individual autoreactive T cells escape from these control mechanisms 
and can mount an immune response against self. An immune response against self is called 
autoimmune disease and can be classified into organ specific such as type I diabetes and 
Addison’s disease and systemic such as systemic lupus erythematosus and rheumatoid arthritis. 
Around 7-9% of the world population is affected by autoimmune diseases (169) and almost all 
of them disproportionally affect women (170). Despite the relative rarity of autoimmune 
diseases, they cause high individual suffering, socioeconomic costs and are one of the most 
common causes for death in young to middle-aged women in the USA (171). 
5.1 RHEUMATOID ARTHRITIS  
Rheumatoid arthritis (RA) is a chronic 
multifactorial disease that leads to severe 
inflammation and destruction of articular joints 
and affects up to 0.5% of the human population, 
with a female to male preponderance of 3 to 1. 
The disease process leading to RA is believed to 
be initiated many years before clinical onset by 
the loss of tolerance to self-antigens.  RA patients 
suffer from symmetrical joint inflammation 
characterized by lymphocytic cell infiltration, 
synovial hyperplasia and pannus formation that 
starts in the distal joints of hands and feet. RA is 
characterized by the presence of auto-antibodies such as rheumatoid factor (RF) and anti-
citrullinated protein antibodies (ACPA), the latter of which is highly specific for RA and both 
can be found in serum many years before the onset of clinical disease (172). RA diagnosis 
requires patients to show symptoms in several categories and is based on criteria defined by 
the American College of Rheumatology and the European League Against Rheumatism 
(EULAR): 
2010 ACR/EULAR Diagnostic criteria for RA 
Categories Score 
Join involvement 
• 1 large joint 
• 2-10 large joints 
• 1-3 small joints (with or without large joint involvement) 
• ≥4-10 small joints (with or without large joint involvement) 
• >10 joints (with at least 1 small joint involved) 
 
0 
1 
2 
3 
5 
Serology (at least 1 test result is needed for classification) 
• negative RF and negative ACPA 
• low positive RF or low positive ACPA 
• high positive RF or high positive ACPA 
 
0 
2 
3 
Acute-phase reactant (at least 1 test result is needed for classification) 
• normal CRP and normal ESR 
• abnormal CRP or abnormal ESR 
 
0 
1 
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Duration of symptoms 
• <6 weeks 
• ≥6 weeks 
 
0 
1 
                    CRP: c-reactive protein; ESR: erythrocyte sedimentation rate                  Score ≥6 definite RA 
Despite the main characteristic being joint inflammation, is RA a systemic autoimmune disease 
with many extra-articular manifestations such as nodule formation, vasculitis, 
keratoconjunctivitis, pleural disease and atherosclerosis which bring on a high risk for 
morbidity and premature death (173). Furthermore, RA is a heterogeneous disease as illustrated 
by the fact that not all patients develop ACPAs, that some risk factors are only associated to 
either ACPA+ or ACPA- RA and that different subsets have different disease etiologies (174). 
RA is a multifactorial disease and both genetic and environmental factors have been shown to 
contribute to the risk of developing RA. Based on twin studies, genetic factors contribute 60% 
of the total risk, with MHC-II HLA-DR alleles being by far the most prominent ones. These       
MHC-II alleles share a short stretch of amino acids in their peptide binding groove that gave 
rise to the “shared epitope hypothesis” which implies a direct involvement of T and B cells in 
RA pathogenesis (175). This is further underpinned by association with genes important in the 
regulating of T cells, such as PTPN22 and CTLA-4 (176). Environmental risk factors are very 
diverse and include smoking, some infections, periodontitis caused by P. gingivalis, exposure 
to mineral oils, lower socioeconomic status and a birth weight above 4kg (177).     
5.1.1 Treatment of rheumatoid arthritis 
The aim for the treatment of RA is to achieve remission or low disease activity. Treatments are 
more efficient in the early stages of disease, known as the “window of opportunity” for RA 
therapy (178) and therefore, the EULAR 2013 recommendations are that treatment with disease 
modifying anti-rheumatic drugs (DMARDs) should commence as soon as a diagnosis has been 
made (179). The first choice is methotrexate (MTX), an antifolate agent that inhibits the 
dihydrofolate reductase. MTX was originally developed as a cancer chemotherapy, however in 
1951 it was shown that low-dose MTX is an effective treatment for autoimmune diseases (180). 
Whilst high-dose MTX inhibits DNA, RNA and protein synthesis and leads to cell-cycle arrest, 
low-dose treatment seems to function differently, at least in vivo, as administration of folate to 
limit cytotoxicity does not limit clinical efficacy (181). Several potential mechanisms of action 
have been proposed, amongst them generation of reactive oxygen species, downregulation of 
adhesion molecules and modified cytokine profiles (182).  
If MTX treatment alone is not sufficient, biological DMARDs can be used additionally. First 
in line are TNFα inhibitors (Infliximab, Etanercept etc.) that have been shown to be remarkably 
effective in the treatment of RA. However, the effect is only transient, requiring frequent 
retreatments and around a third of patients does not respond, likely due to the heterogeneity of 
RA (183). Alternative approved biological DMARDs target the IL-6 receptor (Tocilizumab), 
deplete B cells (Rituximab) (184) or affect the APC’s costimulatory capacity and thus limit     
T cell activation (Abatacept). RA treatment is further complicated by the heterogeneity of 
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disease as it has been shown that ACPA+ and ACPA- disease require different treatment 
regimens (185).  
5.1.2 Regulatory T cells and CTLA-4 in rheumatoid arthritis  
Treg cells have been shown to modulate arthritis in mice as depletion enhances disease whereas 
transfer ameliorates disease (186-188). In RA patients however, the role of Treg cells is not as 
clear. While there is no consensus on frequencies of peripheral blood Treg cells in RA patients, 
most studies report increased frequencies in synovial fluid (189). Yet it remains controversial 
whether Treg cells at the site of inflammation are fully functional (190-194) or if it is the 
synovial effector T cells that have become resistant to suppression (195). TNFa, a key 
inflammatory cytokine in the pathogenesis of RA, inhibits Treg cells via dephosphorylation of 
FOXP3 and treatment with anti-TNFa restores Treg cell function, thereby potentially 
explaining some of the success of this therapy in RA (191). 
Defects in CTLA-4 regulation have been reported to contribute to the abnormal Treg cell 
function observed in synovial fluid of RA patients (196, 197) and certain polymorphisms in 
the Ctla‑4 gene are associated with an increased risk of developing RA (198). Its importance 
in RA is further underlined by the successful therapeutic treatment with CTLA-4Ig fusion 
protein (Abatacept) (179, 199).  
5.2 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a complex chronic autoimmune disease of the CNS with progressive 
neuronal demyelination. There is a female to male preponderance of two to one and disease 
can be either relapsing-remitting or progressive. Symptoms cover a wide variety of 
neurological disorders such as difficulty of speech, ataxia and paralysis depending on in which 
CNS area inflammatory infiltrates are located. The exact cause of MS is unknown but      
myelin-specific CD4+ Th1 and Th17 cells have been shown to play a role in the initiation of 
neuropathology and both genetic and environmental factors are believed to be involved. 
Currently, there is no cure for MS and treatment aims at reducing disease activity and slowing 
disease progression (200).  
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6 ANIMAL MODELS FOR AUTOIMMUNE DISEASES 
Due to the complex nature of most autoimmune diseases, with contributions from many genes 
and environmental factors, finding the underlying disease mechanism in patients is very 
difficult. This is why animal models are often used as a tool since the genetic as well as the 
environmental background can be controlled. Due to the complexity of most autoimmune 
diseases, no single animal model can recapitulate the entire spectrum of heterogeneous human 
diseases but each model is suitable to study one or more specific features of the corresponding 
human disease. Animal models are especially valuable in diseases where patient biopsies can 
only be obtained postmortem, as for example brain samples of MS patients.    
6.1 MOUSE MODELS FOR RHEUMATOID ARTHRITIS 
There are many different mouse models for RA and they can be divided into spontaneous and 
induced models. Spontaneous models include TNFa overproducing transgenic mice, the TCR 
transgenic K/BxN model and the SKG model, although arthritis development in this model 
often requires an i.p. injection of mannan. Examples of induced RA models include         
glucose-6-phosphate isomerase (GPI)-induced arthritis, collagen-antibody-induced arthritis 
and the most commonly used and best studied, collagen-induced arthritis. All of these models 
mimic one or more hallmarks of RA, making them very well suited to study these specific 
aspects but one should be aware that no animal model mimics RA to 100%. For example, 
ACPAs, one of the most prominent features of RA, have so far not been found in any animal 
model.  
6.1.1 Collagen-induced arthritis 
Collagen-induced arthritis (CIA) is induced in susceptible mouse strains by the intradermal 
injection of heterologous type-II collagen (CII), the predominant component of articular joint 
cartilage, in Complete Freund’s adjuvant (CFA) often followed by a booster immunization with 
CII in Incomplete Freund’s adjuvant (IFA) 21-35 days later. CIA closely resembles RA, 
exhibiting erythema, synovial hyperplasia, influx of inflammatory cells, pannus formation and 
bone erosion. The major genetic factor determining arthritis susceptibility is MHC-II,         
HLA-DR4 molecules in RA and H2-q,r and b haplotypes in CIA (201). These H2 molecules 
have been shown to bind the galactosylated immunodominant T cell epitope CII256-270 on rat 
CII with high affinity, whereas the endogenous mouse CII epitope that only differs by a single 
amino acid shows much weaker binding (202). CIA is T- and B cell dependent and both cell 
types reactive to glycosylated CII can be found in RA patients (203-206). Pro-inflammatory 
cytokines, and especially IFNg, IL-17 and TNFa are involved in CIA pathogenicity (207), 
whereas Treg cells have a mitigating effect (186-188). In our own studies, we could show that 
CTLA-4 is an important regulator of all stages of CIA and that CTLA-4 expressed by Tconv 
cells and Treg cells regulates the priming and inflammatory tissue attack respectively         
(Paper II). Furthermore, loss of CTLA-4 can break established T cell tolerance in mice       
(Paper II), whereas high CTLA-4 expression can confer a protective phenotype on T cells with 
increased inherent joint reactivity (Paper III). 
 30 
6.2 MOUSE MODELS FOR MULTIPLE SCLEROSIS  
Just like for RA, multiple mouse models exist for MS and they can also be roughly divided into 
spontaneous and induced models. Spontaneous MS models are based on mice that express 
TCRs or BCRs transgenic for CNS proteins, such as the 2D2 or IgHMOG mice that have myelin 
oligodendrocyte glycoprotein (MOG) specific T or B cells respectively. Induced models can 
be initiated by infection with a virus, such as Theiler’s murine encephalomyelitis virus, through 
treatment with toxins such as cuprizone or through the immunization of susceptible mice with 
self-CNS proteins in CFA. The latter is termed experimental autoimmune encephalomyelitis 
and will be described in more detail below. A major advantage of MS models compared to 
murine RA models is that disease can be transferred by activated CNS specific T cells (208). 
6.2.1 Experimental autoimmune encephalomyelitis  
Experimental autoimmune encephalomyelitis (EAE) is the most widely used model for MS. 
EAE is induced in susceptible mouse strains by the intradermal injection of self-CNS proteins 
such as MOG, myelin basic protein (MBP), proteolipid protein (PLP) or spinal cord 
homogenate in CFA. An additional injection of pertussis toxin is often required. Paralysis 
typically starts in the tail tip and progresses from there in a caudal to cranial fashion. Depending 
on the genetic background, EAE is either monophasic (C57BL) or relapsing-remitting (SJL/J). 
Pro-inflammatory cytokines like IFNg, IL-23, IL-17 and GM-CSF are crucial for disease 
development in EAE and both Th1 and Th17 cells from immunized mice can transfer disease 
to naïve recipients (208). The dependency on B cells is less stringent, as MOG1-125 protein 
induced EAE is dependent on B cells, whereas B cells are not required but can modulate disease 
severity in MOG peptide induced EAE (209, 210).    
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7 PRESENT INVESTIGATIONS 
This thesis comprises four studies, all of which deal with various aspects of regulation of 
autoimmunity. Paper I focuses on the spontaneous development of systemic autoimmunity in 
adult mice upon loss of CTLA-4 and that this loss can have disease promoting as well as 
protecting effects in different models of induced autoimmunity. Paper II looks more 
specifically into the role of CTLA-4 in the regulation of CIA, at which stage of disease and on 
which cell types CTLA-4 is important. Furthermore, the differential role of CTLA-4 in 
response to heterologous and autologous CII is studied. In Paper III, we study a novel model 
of tolerance induction in mice with increased inherent CII reactivity and the role of CTLA-4 
on CII specific T cells. Paper IV deals with the more general question of whether bacteria in 
the gut microbiota have an impact on arthritis susceptibility in ROS deficient Ncf1 mice that 
have a predisposition to infections, inflammation and CIA.  
7.1 PAPER I 
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. 
In this study, we focus on the role of CTLA-4 in the regulation of the adult immune system 
since most of our knowledge about CTLA-4 stems from KO mice that succumb to 
autoimmunity after a few weeks of life. We established a tamoxifen induced, Cre driven   
CTLA-4 depletion in adult mice, termed induced KO (iKO) mice. iKO mice developed 
profound lymphoproliferation, multi-organ lymphocytic cell infiltrations and 
hypergammaglobulinemia, reminiscent of germline and congenital CTLA-4 deficiency, albeit 
without reaching lethality. We showed that organ infiltration was accompanied by production 
of specific autoantibodies, a functional deficit in affected organs and that Treg and Tconv cells 
infiltrated into tissues simultaneously. Kinetic studies further revealed that Treg cells were 
more sensitive to loss of CTLA-4 and proliferated before levels of CTLA-4 where completely 
diminished, whereas Tconv cell numbers only started to increase upon complete loss. This led 
to an increased Treg:Tconv cell ratio, which together with the simultaneous tissue infiltration, 
could be the explanation why induced loss of CTLA-4 does not progress to fatal autoimmunity. 
Furthermore, T cell transfer studies into T cell deficient hosts revealed that thymic and 
peripheral T cells from iKO donors caused different pathologies, indicating a role for CTLA-4 
in thymic selection and the shaping of the TCR repertoire. Finally, with the help of different 
models of autoimmunity, we could show that there is no default pathway of CTLA-4 regulation 
but that loss of CTLA-4 instead can have disease promoting or inhibiting effects, likely 
depending on the local milieu and the type of cells involved in the disease specific immune 
response.  
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7.2 PAPER II 
CTLA-4 expressed by FOXP3+ Treg cells prevents inflammatory tissue attack and not    
T cell priming in arthritis. 
In this study, we performed an in-depth analysis of how CTLA-4 regulates CIA. In a first set 
of experiments we studied the different disease stages of CIA and could show that CTLA-4 is 
not involved in T cell priming but rather in the effector phase of disease and also in the 
spreading of disease to previously unaffected limbs in the chronic phase. Despite the disease 
enhancing effect of loss of CTLA-4, effects on CII specific T and B cell responses were minor 
to non-existent. Since CIA is induced with heterologous rat CII, not all aspects of tolerance 
towards a true self-antigen are reflected and this could influence CTLA-4 mediated regulation. 
Therefore, iKO mice were crossed to mouse mutated collagen (MMC) mice, that express rat 
CII in a joint restricted fashion and are thus protected from CIA due to their T cells being 
naturally tolerized towards the immunodominant rat CII epitope. Loss of CTLA-4 completely 
broke tolerance in MMC+ mice, independent of depletion occurring before priming or at 
disease onset. Contrary to the heterologous setting however, loss of CTLA-4 in the autologous 
MMC setting led to elevated autoreactive T cell responses. Hence CTLA-4 appears to regulate 
the priming of autoreactive but not heteroreactive T cells, whereas the onset of arthritis is 
regulated in both cases. In MMC+ mice, loss of CTLA-4 specifically at the onset of disease led 
to elevated antibody titers against CII, which might be due to enhanced germinal center 
reactions caused by loss of CTLA-4 in T follicular regulatory cells. With the help of inducible          
Foxp3-Cre mice, we could further distinguish between cell type specific effects of CTLA-4, 
since it is expressed on both Tconv as well as Treg cells. We could show that loss of CTLA-4 
on Tconv cells is responsible for enhanced arthritis susceptibility during the priming of 
autoreactive T cells, whereas Treg cell specific CTLA-4 is crucial for maintaining tolerance at 
the secondary encounter with antigen and to protect the joints from being attacked by a 
destructive inflammatory response.           
7.3 PAPER III 
Tolerized collagen-reactive T cells are enriched in the liver and protect from collagen-
induced arthritis. 
CTLA-4 is a major regulator of both the naïve immune system as well as autoimmunity and 
has been implicated in the impaired Treg cell function and bone erosion observed in RA 
patients. However, defining the exact role of CTLA-4 in RA has been hampered by the 
difficulty to identify and isolate extremely rare antigen-specific T cells. Hence, in this study, 
we employed single TCR b-chain transgenic Vb12 mice whose T cells are specific to the 
galactosylated immunodominant epitope of rat CII in case of recombination with endogenous 
TCR Va16 with a specific CDR3 region. We crossed Vb12 mice to iKO mice and used the 
previously generated clonotypic antibody B22a.1 to identify CII-reactive T cells and to 
discriminate the effect of loss of CTLA-4 on antigen-specific vs. total T cells. The inherent T 
cell predisposition to joint reactivity made Vb12 mice highly susceptible to CIA, independent 
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of CTLA-4 status. In a subimmunogenic approach consisting of CII emulsified in IFA 
however, Vb12+ mice were completely protected from disease and this was dependent on 
CTLA-4, which was highly expressed first by CII-specific Tconv cells and later on by all 
T cells. Despite this resistance to clinical arthritis, T cells from Vb12+ mice were functionally 
primed in vivo and had full effector functions ex vivo. B cells in protected Vb12+ mice however 
failed to produce CII-specific antibodies but a general defect in antibody production could be 
excluded. Surprisingly, CII-specific T cells were found to be enriched in the liver and adoptive 
transfer of total liver lymphocytes from protected Vb12+ donors could suppress disease 
development in otherwise susceptible Vb12- recipients. Further studies will be needed to 
elucidate whether CII-reactive T cells are expanded and tolerized locally in the liver or whether 
peripherally tolerized T cells accumulate in the liver due to cross-reactivity to an unknown liver 
antigen.         
7.4 PAPER IV 
Germ-free mice deficient of reactive oxygen species have increased arthritis 
susceptibility. 
Both patients suffering from chronic granulomatous disease (CGD) and ROS deficient Ncf1 
mice have an increased susceptibility to microbial flora provoked inflammation and are also 
more likely to develop autoimmune diseases. This paper deals with the longstanding and 
unresolved question whether the increased inflammation in the above individuals is causative 
for the increased development of autoimmune diseases, or whether these are two parallel 
phenomena. We therefore generated germ-free Ncf1 mice and studied their susceptibility to 
CIA in comparison to the same mice reared in specific pathogen-free (SPF) conditions. 
Additionally, SPF Ncf1 mice were treated with antibiotics to partially deplete their microbial 
flora. We could show that the absence of commensal bacteria had no effect on CIA 
development in germ-free Ncf1 mice and neither did the partial reduction in SPF Ncf1 mice 
treated with antibiotics. All Ncf1 mice retained their high susceptibility to CIA compared to 
WT littermates and had similar T- and B cell responses to CII, independent of their commensal 
status. This is a strong indication that increased susceptibility to autoimmunity in ROS deficient 
Ncf1 mice is not secondary to defective host defense against bacteria but rather due to a specific 
effect on adaptive responses to CII. Since ROS production in CD68+ macrophages reduces CIA 
susceptibility down to WT levels and CIA has been shown to be T cell dependent but T cells 
themselves do not produce ROS, it is likely that T cells are exposed to and influenced by ROS 
during antigen presentation.        
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8 CONCLUDING REMARKS AND FUTURE PERSPECTIVE 
Even though immunology researchers today are very familiar with the term Treg cells and 
consider them a well-established member of the T cell family, we should not forget that the 
field of FOXP3+ Treg cell biology has in fact been discovered less than 20 years ago. And even 
though major advances have been made in those scarce 20 years, we are still far from fully 
understanding the development and function of this cell population, especially on the individual 
cell level. Even though the field of autoimmunity and RA is much older in comparison, also 
here our knowledge is far from complete. We still do not know what initiates RA and why the 
disease course is so heterogeneous. Furthermore, current treatment of RA is not 
preventive/curative, requires life-long intake of medicine and a large proportion of patients 
does not respond satisfactorily. The treatment goal for every autoimmune disease would be of 
course to reinstall tolerance to self and Treg cells are the most promising candidate for this and 
CTLA-4 especially, since it has been shown to be vital for the prevention of autoimmunity. 
Reinstallation of tolerance requires however a more detailed understanding of Treg cells both 
in health and in autoimmunity, in order to decipher how they normally function and why they 
do not function properly in autoimmunity. The four papers presented in this thesis aim to 
increase this knowledge by dealing with various aspects of CTLA-4 mediated regulation of 
Treg cells. They add to existing knowledge bringing us one step closer to the goal. However, 
for every two steps forwards, one step backwards is taken as new questions are thrown up. For 
example, recent years have shown that Treg cells are not a homologous population but that 
there are tissue specific Treg cells that can look and behave very differently. Additionally, 
autoimmune diseases are very different even though they are believed to share some common 
genes and pathways. Throw these two together and the complexity will increase exponentially. 
We have shown this impressively with the observation that loss of CTLA-4 enhances 
susceptibility to arthritis but in fact protects from experimental encephalomyelitis. Not only the 
disease as such but also the initiating factors seem to influence the effect of CTLA-4, as mice 
were protected from peptide but not protein induced EAE. Likewise intriguing is our finding 
that the age at loss of CTLA-4 is in fact the difference between life and death. Whereas mice 
born with CTLA-4 deficiency succumb to fatal autoimmunity shortly after birth, adult 
deficiency has a much milder phenotype that is not lethal. 
Hence, in the future we will need to consider many aspects when studying CTLA-4 as a 
modulator of tolerance and autoimmune diseases: the initiating factor, the place of action, the 
different cell types involved, how these interact, the local milieu and probably many more. This 
seems to be a truly overwhelming task but if we slowly add piece by piece to the puzzle even 
if we do not know how they are connected at the moment, eventually we will be able to piece 
them together to see a complete picture! 
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for treating me like one of yours and for showing me that I can feel at home anywhere in the 
world! I am so happy we are still in touch even though I am always like half a year behind the 
calendar! Ellen and Per, for showing me what real working life means, for letting me put my 
ideas into practice, for always having a bed for us no matter how spontaneous the visit and for 
many visits in Stockholm. Peder for letting me experience a lot of things, converting me from 
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skier to snowboarder and for being the brother I never had. Last but not least, my German 
family. Frau Geisen, for looking after us when we were small, making the best lasagna and 
still spoiling us at every occasion. Evamarie, for being the best godmother on earth, supplying 
me with hand-knitted woolen socks and making sure we are the best equipped household with 
knives in Sweden. Oma, for precious handwritten letters and for keeping me updated about the 
rest of the family and vice versa. Mone, my big (small) sister. For making sure I never run out 
of shower gel or candy and for many Skype calls. Mama and Papa, I know one cannot choose 
one’s parents but even if I could, I would not have chosen anyone else! You are always 
supportive, let me try out new things, learn from my own mistakes and always let me know 
that you will be there for me no matter what! Thank you for sparing us the Stockholm apartment 
move marathon! Mama, for you attitude of “you can throw eggs around if you are really mad 
as long as you clean up after yourself”. Papa for teaching me all about fixing things and for 
helping me in putting my projects into action.  
Last but not least, an immense thank you to Moritz who has accompanied me for more than 
10 years and who is there to catch me when I most need it. Your love, support and 
understanding makes anything possible. Thank you for challenging my comfort zone from time 
to time, for trekking adventures, shared love of being outdoors, surprising me with small gifts, 
for knowing exactly what I love and need, for your ability to be as childish as myself. I love 
you and cannot wait to discover small aspects of you in our little one!     
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